Belvedere Trading’s Anavex Life Sciences AVXL Stock Holding History

Belvedere Trading’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-19,500	Closed	-$231K	–	1132
2022 Q3	$231K	Buy	+19,500	New	+$206K	0.01%	138

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Summit Financial Parsippany, New Jersey $9.12B AUM 27.44% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Belvedere Trading's AVXL Position: Q4 2022 in Review

Belvedere Trading sold out of Anavex Life Sciences (AVXL) in Q4 2022, closing a stake of 582 shares — an estimated $6.22K sold.

Belvedere Trading first reported a position in AVXL in Q3 2022 and held it in 1 quarter. The position peaked at $7K in Q3 2022. 139 funds tracked by Wall St. Rank hold AVXL as of Q4 2022.

Belvedere Trading reported no remaining Anavex Life Sciences position as of Q4 2022 after selling out during the quarter.
Belvedere Trading sold 582 Anavex Life Sciences shares in Q4 2022, an estimated $6.22K.
Belvedere Trading first reported a position in Anavex Life Sciences in Q3 2022 and held it in 1 quarter.
Belvedere Trading's Anavex Life Sciences position peaked at $7K in Q3 2022.
139 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q4 2022.

Based on Belvedere Trading's 13F filing for Q4 2022, filed 15 Feb 2023.